Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul 24;12:502.
doi: 10.3389/fnins.2018.00502. eCollection 2018.

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials

Affiliations
Free PMC article
Review

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials

Rafael M Bitencourt et al. Front Neurosci. .
Free PMC article

Abstract

Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience. This disorder affects approximately 10% of people at some point in life. Current pharmacological therapies for PTSD have been shown to be inefficient and produce considerable side effects. Since the discovery of the involvement of the endocannabinoid (eCB) system in emotional memory processing, pharmacological manipulation of eCB signaling has become a therapeutic possibility for the treatment of PTSD. Cannabidiol (CBD), a phytocannabinoid constituent of Cannabis sativa without the psychoactive effects of Δ9-tetrahydrocannabinol, has gained particular attention. Preclinical studies in different rodent behavioral models have shown that CBD can both facilitate the extinction of aversive memories and block their reconsolidation, possibly through potentialization of the eCB system. These results, combined with the currently available pharmacological treatments for PTSD being limited, necessitated testing CBD use with the same therapeutic purpose in humans as well. Indeed, as observed in rodents, recent studies have confirmed the ability of CBD to alter important aspects of aversive memories in humans and promote significant improvements in the symptomatology of PTSD. The goal of this review was to highlight the potential of CBD as a treatment for disorders related to inappropriate retention of aversive memories, by assessing evidence from preclinical to human experimental studies.

Keywords: aversive memories; cannabidiol; endocannabinoid system; fear conditioning paradigm; post-traumatic stress disorder.

Figures

FIGURE 1
FIGURE 1
Brief history of advances in research on the use of CBD in PTSD.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Abush H., Akirav I. (2009). Cannabinoids modulate hippocampal memory and plasticity. Hippocampus 20 1126–1138. 10.1002/hipo.20711 - DOI - PubMed
    1. Adams R., Hunt M., Clark J. H. (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J. Am. Chem. Soc. 62 196–200. 10.1021/ja01858a058 - DOI
    1. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.-H., Vogel Z., et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353 23–31. 10.1016/S0014-2999(98)00392-6 - DOI - PubMed
    1. Berardi A., Schelling G., Campolongo P. (2016). The endocannabinoid system and post traumatic stress disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings. Pharmacol. Res. 111 668–678. 10.1016/j.phrs.2016.07.024 - DOI - PubMed
    1. Bergamaschi M. M., Queiroz R. H. C., Zuardi A. W., Crippa J. A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6 237–249. 10.2174/157488611798280924 - DOI - PubMed

LinkOut - more resources

Feedback